The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
284
NBI-1117568 will be administered per schedule specified in the arm description.
Placebo will be administered per schedule specified in the arm description.
Neurocrine Clinical Site
Bryant, Arkansas, United States
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
Time frame: Baseline, Week 5
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 5
Time frame: Baseline, Week 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGNeurocrine Clinical Site
Anaheim, California, United States
RECRUITINGNeurocrine Clinical Site
Pico Rivera, California, United States
RECRUITINGNeurocrine Clinical Site
San Diego, California, United States
RECRUITINGNeurocrine Clinical Site
Sherman Oaks, California, United States
RECRUITINGNeurocrine Clinical Site
Torrance, California, United States
RECRUITINGNeurocrine Clinical Site
Hollywood, Florida, United States
RECRUITINGNeurocrine Clinical Site
Miami Lakes, Florida, United States
RECRUITINGNeurocrine Clinical Site
Atlanta, Georgia, United States
RECRUITING...and 11 more locations